Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property

PHILADELPHIA, June 06, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights...
August 13, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Board Appoints New President

PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new...
May 26, 2015 12:46 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)

PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
May 11, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
January 15, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Awarded $770,852 by Federal Judge

WILMINGTON, Del., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that after prevailing in a federal lawsuit brought against the...
October 20, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit

PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that a federal judge in Delaware has dismissed all claims...
March 10, 2014 11:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries

PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning...
March 10, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees

PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx"), announced that after more than a week in trial, a federal jury in Atlanta...